Ordering
Available Variants10 mg
CHA.41658-10mg
Price
€57.28
Available – Dispatch in 14 days
50 mg
CHA.41658-50mg
Price
€231.20
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.41658-10mg | €57.28 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.41658-50mg | €231.20 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C19H22N6O3S |
|---|---|
| CAS Number | 1394076-92-6 |
| Molecular Weight | 414.48 |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
| MDL number | MFCD28900677 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
GNE-317, also known by its CAS identifier 1394076-92-6, is a small molecule inhibitor that has been investigated for its potential therapeutic applications. This compound has been shown to exhibit inhibitory activity against specific molecular targets, which are implicated in various disease processes. The mechanism of action of GNE-317 involves the modulation of key signaling pathways, leading to the suppression of pathological cellular responses. As a result, GNE-317 may have potential utility in the treatment of certain diseases, where the targeted molecular pathways play a critical role. Further research is necessary to fully elucidate the effects of GNE-317 and to explore its potential as a therapeutic agent, including the evaluation of its efficacy and safety in preclinical and clinical settings. Additional studies will help to determine the potential benefits and limitations of GNE-317.
